Current status of immune checkpoint inhibition in early-stage NSCLC
Author:
Funder
University Hospitals KU Leuven: MSD
AstraZeneca
Boehringer-Ingelheim
Cancer Belgium
Christie NHS Foundation Trust
Swiss Cancer League
Swiss Group for Clinical Cancer Research
SAKK
Foundation Medicine
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz175/28856417/mdz175.pdf
Reference69 articles.
1. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016
2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018
3. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann Oncol,2017
4. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer;Arriagada;N Engl J Med,2004
5. Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage IV NSCLC be translated in the earlier stages?;Deslypere;Ther Adv Med Oncol,2018
Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The analysis of multiple omics and examination of pathological images revealed the prognostic and therapeutic significances of CD93 in lung squamous cell carcinoma;Life Sciences;2024-02
2. Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis;Cancer Investigation;2024-01-15
3. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B;Cancer;2024-01-02
4. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma;Cell Cycle;2024-01-02
5. Progress in Immunotherapy of Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3